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Editorial
Using kitchen scales, carefully weight out 4 kilograms 
of rice and pour it into a deep saucepan. Now put your hands 
into the rice and let the grains run between your fingers. 
Contemplate carefully each grain. The number of grains 
(about 140,000) is approximately the number of lives that 
could be saved each year world-wide if all hospitalized 
trauma patients with significant bleeding were treated with 
tranexamic acid (TXA) within 3 hours of injury. TXA is 
cheap and widely available. All that is needed to reap these 
human benefits is that doctors use it.
That TXA is a potent inhibitor of fibrinolysis was first 
reported by Shosuke and Utako Okamoto in The Keio 
Journal of Medicine in September 1962.1 Since then TXA has 
been widely used to treat heavy menstrual bleeding and to 
reduce blood loss in elective surgery where it reduces blood 
transfusion by about one third.2 The CRASH-2 collaborators 
hypothesized that TXA might also reduce bleeding in trauma 
patients. The CRASH-2 trial was a UK government funded 
randomized trial of the effects of the early administration 
of TXA on death, vascular occlusive events and blood 
transfusion in bleeding trauma patients. A total of 20,211 
adults with significant traumatic bleeding were randomized 
to receive TXA or matching placebo, with 99.6% follow-up. 
The risk of death due to bleeding was significantly reduced 
with TXA. If TXA is given within three hours of injury, it 
reduces the risk of bleeding to death by nearly one third 
(relative risk = 0.72 [95%CI 0.63-0.83], p < 0.001). All 
cause mortality was also significantly reduced.3, 4 The large 
numbers of patients studied in a wide range of different health 
care settings help these results to be generalized widely. On 
the basis of the results of the CRASH-2 trial, TXA has been 
included in the WHO list of essential medicines.5 Giving TXA 
to bleeding trauma patients within three hours of the injury 
could save over 100,000 lives per year world-wide. Giving 
TXA to bleeding trauma patients is highly cost effective in 
high, middle and low income countries.6 It is essential that 
all doctors who treat trauma patients are aware of the results 
of the CRASH-2 trial. TXA should be given to all adults 
with significant hemorrhage (systolic bleed pressure < 90 
mmHg, heart rate > 110 beat/min) or those considered by the 
clinician to be at risk for significant hemorrhage. Because the 
effect of tranexamic acid on death due to bleeding depends 
importantly on the time interval between the injury and the 
onset of treatment it should be given as early as possible 
and within 3 or 4 hours of the injury as it is unlikely to be 
effective if given later than this.
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